Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
Gimv [BE0003699130/GIMB]   
[20/03/2020]

Gimv : Ahead of expected further sector consolidation, Belgian wallpaper producer Grandeco expands its shareholder base, with Down2Earth replacing Gimv as majority shareholder

Antwerpen BE, 20 March 2020, 07:30 CET embargo Ahead of expected further sector consolidation, Belgian wallpaper producer Grandeco expands its shareholder base, with Down2Earth replacing Gimv as majority shareholder Grandeco announces a reorganisation of its shareholder base: Down2Earth Capital D2E comes in as majority shareholder, while Gimv and... See more
 
Gimv [BE0003699130/GIMB]   
[02/03/2020]

Gimv : Gimv invests in AME, specialised producer of smart electronics for tomorrow’s products, located in Eindhoven Brainport

Antwerpen BE / Eindhoven NL, 2 March 2020, 07:30 CET embargo Gimv invests in AME, specialised producer of smart electronics for tomorrow’s products, located in Eindhoven Brainport Gimv acquires a majority share in Applied Micro Electronics “AME”, a developer and manufacturer of innovative, highquality and smart electronic modules for international OEM... See more
 
Gimv [BE0003699130/GIMB]   
[20/02/2020]

Gimv : Gimv to enter partnership with Köberl Group to achieve further growth in the facility management and technical building services sector

Munich, 20 February 2020, 17:50 CET Gimv to enter partnership with Köberl Group to achieve further growth in the facility management and technical building services sector Gimv acquires a majority stake in Munichbased Köberl Group, including Fink Gebäudetechnik GmbH & Co. KG and GEMA Gebäudemanagement GmbH & Co. KG. The aim of the partnership is to... See more
 
Gimv [BE0003699130/GIMB]   
[04/12/2019]

Gimv : Imcheck Therapeutics raises USD 53 million, Gimv increases its investment in the immuno-oncology space

Antwerp/Marseille, 4 December 2019, 6:45 AM CET Imcheck Therapeutics raises USD 53 million, Gimv increases its investment in the immunooncology space In a Series B financing round of USD 53 million, Gimv is increasing its investment in French ImCheck Therapeutics www.imchecktherapeutics.com, an emerging player in the field of cancer and autoimmune ... See more
 
Gimv [BE0003699130/GIMB]   
[21/11/2019]

Gimv : Further growth and continuing strong portfolio results

Antwerp, 21 November 2019, 7:00 CET Further growth and continuing strong portfolio results Managing Director Koen Dejonckheere, on the past halfyears results: “With a persistent strong pace of investment, Gimv grew its portfolio further to its present level of EUR 1.2 billion. Our portfolio companies achieved attractive results in an uncertain... See more